Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doxorubicin-induced chemokine receptor expression study in breast cancer and sarcoma
NL-OMON51299Completed
- Sponsor
- Leiden University Medical Center
- Start
- May 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of doxorubicin in breast cancer and Bone and soft tissue sarcoma (2 cohorts), sponsored by Leiden University Medical Center. Primary endpoint: CXCR1 and CXCR2 expression on immune cells. Started May 2024; status: completed.
02
Drugs
doxorubicin
03
Conditions
breast cancerBone and soft tissue sarcoma
Beyond the preview
Go deeper on NL-OMON51299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51299.